"Even though naxitamab appeared to have erased the cancer, Dr. Modak wanted to do everything possible to prevent the high-risk neuroblastoma from returning. He proposed that James receive a pioneering treatment: a cancer vaccine that would train his immune system to continuously be on guard to spot and fight malignant cells." Read more: https://www.mskcc.org/news/cancer-vaccine-could-prevent-neuroblastoma-from-returning-after-antibody-treatment

The study found that restricting the cancer’s access to an essential nutrient called arginine yielded promising results, both when used on its own and when used in combination with standard therapies.  Read more: https://www.ccia.org.au/blog/potential-new-treatment-strategy-for-high-risk-neuroblastoma

Researchers have discovered how circular extra-chromosomal DNA drives relapse in childhood cancers and found a way to target dormant...

A groundbreaking study led by Children’s Hospital Los Angeles has found a novel mechanism behind neuroblastoma progression: the shape and...

Identifying why some patients regress and others don't could help thousands of patients. [...] In mice bred to have tumors that were...

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an...

The National Comprehensive Cancer Network (NCCN) has updated its guidelines to include the category 2A recommendation of a naxitamab-gqgk...

Neuroblastomas are the most common cancer in infants, with about 700–800 diagnoses per year in the US, according to the American Cancer...

Despite advances in treatment, survival rates for high-risk and relapsed/refractory neuroblastoma remain dismal, and options like...

The survival rate for children with a rare but deadly cancer could one day be improved by adding an existing drug—which is currently used...